Tag: HER2+ breast cancer

Olaparib in BRCA+ Breast Cancer

New clinical data show that the PARP inhibitor olaparib (Lynparza, AstraZeneca/Merck) also has a place in the treatment of early stage breast cancer with BRCA...

No Benefit Seen With Everolimus in Early Breast Cancer

Adding everolimus to adjuvant hormone therapy for early ER+, HER2- breast cancer does not offer any benefit over hormone therapy alone, according to results of...

Entinostat Doesn’t Overcome Endocrine Resistance in Breast Cancer

The histone deacetylase (HDAC) inhibitor entinostat failed to overcome resistance to endocrine therapy in hormone receptor–positive, HER2-negative, advanced breast cancer in a phase 3 trial....

Even More Women May Forgo Chemo for Breast Cancer

More women with early-stage breast cancer may safely forgo chemotherapy, suggests an interim analysis that had a median follow-up of 5 years of the large-scale...

Palbociclib Disappoints in HR+, HER2– Breast Cancer

The CDK4/6 inhibitor palbociclib provides no significant benefit in patients with hormone receptor–positive (HR+), HER2-negative primary breast cancer, according to first results from the PENELOPE-B...

What’s Hot, Including a Major Chemotherapy Trial

The “hottest” presentation at the upcoming 2020 San Antonio Breast Cancer Symposium (SABCS) comes from RxPONDER (abstract GS3-00), a major randomized clinical trial assessing use...

pCR in HER2+ Breast Cancer Predicts Long-Term Survival

A pathologic complete response (pCR) to targeted therapy in HER2-positive breast cancer portends good long-term outcomes, according to final results of the phase 3 NeoALTTO/BIG...

FDA Approves First New Drug With International Group

The US Food and Drug Administration today approved the oral therapy tucatinib (Tukysa, Seattle Genetics) for the treatment of advanced HER2-positive breast cancer. This is...